What is identity, really, if not a pattern that keeps reappearing even when the furniture changes? Cancer, annoyingly enough, seems to agree, because a large B-cell lymphoma can leave behind tiny molecular fingerprints in the bloodstream long before a scan fully settles the argument.
That is the premise behind a new study in Journal of Clinical Oncology looking at circulating tumor DNA, or ctDNA, in people with relapsed or refractory large B-cell lymphoma (LBCL) receiving either lisocabtagene maraleucel, better known as liso-cel, or the older standard path of salvage chemo followed by autologous stem cell transplant when possible (Stepan et al., 2026). If that sentence felt like a suitcase packed by an anxious biostatistician, here is the plain-English version: the researchers wanted to know whether a blood test could tell who was truly responding, and whether it could do that better, or at least earlier, than our usual tools.
The Tumor Leaves Receipts
ctDNA is exactly what it sounds like - scraps of DNA shed by tumor cells into the blood. Think of it as the cancer equivalent of glitter at a craft store. Once it is loose, it gets everywhere, and even when the main mess looks cleaned up, a few sparkly bits can still expose what happened.
In this analysis from the phase 3 TRANSFORM trial, researchers studied 136 patients using an ultrasensitive method called PhasED-Seq at several preset time points after treatment (Stepan et al., 2026). The big finding was elegantly rude to anyone who still hopes biology will behave simply: patients whose ctDNA cleared from the blood did better, no matter which treatment arm they were in. But more patients treated with liso-cel reached that ctDNA-negative state, and those remissions looked deeper and more durable.
That matters because LBCL is not a polite disease. It is the most common aggressive non-Hodgkin lymphoma, and when it comes roaring back early after first-line therapy, the old salvage-chemo-then-transplant route often feels less like a plan and more like a dare. CAR-T therapy, including liso-cel, tries a different tactic by taking a patient’s own T cells, engineering them to recognize CD19 on lymphoma cells, and sending them back into circulation like tiny, very motivated bouncers.
CAR-T, Meet Molecular Lie Detector
TRANSFORM already showed that liso-cel beat standard second-line therapy on event-free survival, complete response rate, and progression-free survival (Abramson et al., 2023; Kamdar et al., 2025). This ctDNA paper adds another layer: the blood test was not merely nodding along after the fact. It tracked whether the disease had been knocked down to a level too low for conventional methods to confidently see.
The especially interesting bit is that ctDNA seemed to provide prognostic value beyond PET imaging. PET scans are useful, but they are also the radiologic equivalent of trying to judge a neighborhood by helicopter. You get a broad view, which is helpful, but you may miss the guy in the alley quietly restarting the trouble. In the transplant arm, ctDNA re-emergence after complete response helped flag relapse risk, which is exactly the sort of plot twist clinicians would prefer to catch before the third act catches fire.
This fits with a broader body of lymphoma research suggesting ctDNA is becoming more than a flashy lab trick. Reviews in Blood Cancer Discovery and Leukemia have argued that ctDNA can help with tumor genotyping, response assessment, and measurable residual disease detection, while also highlighting the very non-romantic problems of assay sensitivity, standardization, and clinical implementation (Roschewski et al., 2022; Lauer et al., 2022).
Why You Should Actually Care
If these results hold up and get integrated into routine care, ctDNA could make lymphoma follow-up less like waiting for a smoke alarm and more like having a carbon monoxide detector. Quiet, earlier, and less dependent on obvious disaster.
A good ctDNA test could help answer brutally practical questions: Is this treatment working? Is the remission real, or just cosmetically impressive? Does a patient need closer monitoring, a different therapy, or maybe rescue before the disease becomes clinically obvious again? In a field where timing is everything and relapse can move with the grace of a falling piano, earlier molecular warning is not a luxury.
There are, however, some very earthly limitations. CAR-T is logistically hard, expensive, and available mainly through specialized centers. Expert reviews still describe access, manufacturing time, and cost as major barriers, even while CAR-T keeps reshaping LBCL care (Trabolsi et al., 2024). ctDNA testing has its own headaches too: assays must be ultrasensitive, labs need standardization, and nobody wants to base high-stakes decisions on a test that confuses molecular static for relapse.
Still, the philosophical appeal here is hard to miss. Cancer is not just a lump on a scan. It is a pattern, a process, a set of instructions trying to persist. And this study suggests that if you listen carefully enough to the blood, it may tell you whether that pattern is fading or merely hiding.
References
Stepan L, Ansari S, Abramson JS, et al. Circulating tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. J Clin Oncol. 2026. DOI: https://doi.org/10.1200/JCO-25-03051
Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-1684. DOI: https://doi.org/10.1182/blood.2022018730
Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025. DOI: https://doi.org/10.1200/JCO-25-00399
Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discov. 2022;3(1):5-15. DOI: https://doi.org/10.1158/2643-3230.BCD-21-0029. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9245363/
Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36(9):2151-2164. DOI: https://doi.org/10.1038/s41375-022-01618-w. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9417989/
Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14(1):27. DOI: https://doi.org/10.1038/s41408-024-00997-w. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10853226/
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.